| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study
|
Eyre, Toby A
|
|
|
8 |
12 |
p. e912-e921
|
artikel
|
| 2 |
Acalabrutinib monotherapy in patients with Richter transformation
|
Fischer, Kirsten
|
|
|
8 |
12 |
p. e868-e870
|
artikel
|
| 3 |
A new triplet for chronic lymphocytic leukaemia: zanubrutinib–venetoclax–obinutuzumab
|
Rossi, Davide
|
|
|
8 |
12 |
p. e864-e865
|
artikel
|
| 4 |
Correction to Lancet Haematol 2021; 8: e828–39
|
|
|
|
8 |
12 |
p. e874
|
artikel
|
| 5 |
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
|
Ludwig, Heinz
|
|
|
8 |
12 |
p. e934-e946
|
artikel
|
| 6 |
Follicular lymphoma: is more better or is less really more?
|
Maddocks, Kami
|
|
|
8 |
12 |
p. e865-e867
|
artikel
|
| 7 |
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
|
Kantarjian, Hagop
|
|
|
8 |
12 |
p. e922-e933
|
artikel
|
| 8 |
In defence of individualised medicine
|
Hilal, Talal
|
|
|
8 |
12 |
p. e875
|
artikel
|
| 9 |
Is it time to tailor treatment on the basis of minimal residual disease in multiple myeloma?
|
Oliva, Stefania
|
|
|
8 |
12 |
p. e876-e877
|
artikel
|
| 10 |
Kyle Davis: using his own experience to advocate for his patients
|
Wilkinson, Emma
|
|
|
8 |
12 |
p. e878
|
artikel
|
| 11 |
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
|
Murai, Kazunori
|
|
|
8 |
12 |
p. e902-e911
|
artikel
|
| 12 |
Low-dose dasatinib: when less can be more
|
Amrein, Philip Crawford
|
|
|
8 |
12 |
p. e867-e868
|
artikel
|
| 13 |
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
|
Diefenbach, Catherine
|
|
|
8 |
12 |
p. e891-e901
|
artikel
|
| 14 |
Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy
|
Mackenzie, Strachan
|
|
|
8 |
12 |
p. e870-e873
|
artikel
|
| 15 |
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers
|
Bhatnagar, Bhavana
|
|
|
8 |
12 |
p. e947-e954
|
artikel
|
| 16 |
Removing unfair barriers to blood donation
|
The Lancet Haematology,
|
|
|
8 |
12 |
p. e863
|
artikel
|
| 17 |
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
|
Soumerai, Jacob D
|
|
|
8 |
12 |
p. e879-e890
|
artikel
|
Tijdschrift beschrijving